ExploreWatchlistsPricing
  1. JP-listed companies
  2. Modalis Therapeutics Corporation
  3. Financials
  4. Cash from financing

Modalis Therapeutics Corporation (4883)

Market cap
¥4.9B
P/E ratio
Modernalis develops gene therapies for rare diseases using safe CRISPR-GNDM technology that controls genes without cutting DNA strands.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndCash from financing (Million JPY)YoY (%)
Dec 31, 20251,351-55.63%
Dec 31, 20243,045+150.32%
Dec 31, 20231,216+1810.17%
Dec 31, 202264-12.32%
Dec 31, 202173-97.39%
Dec 31, 20202,778+11.54%
Dec 31, 20192,491

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat